Patients with plaque psoriasis will be enrolled. They will be dosed with repeated intravenous
doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the
pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups
will occur at random, and the actual treatment will not be revealed to the investigator or to
the patient during the trial.